Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
11.66
-0.34 (-2.83%)
Feb 21, 2025, 4:00 PM EST - Market closed
Bicycle Therapeutics Employees
Bicycle Therapeutics had 284 employees as of December 31, 2023. The number of employees increased by 48 or 20.34% compared to the previous year.
Employees
284
Change (1Y)
48
Growth (1Y)
20.34%
Revenue / Employee
$129,923
Profits / Employee
-$585,479
Market Cap
805.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BCYC News
- 17 days ago - Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 19 days ago - Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data - Seeking Alpha
- 5 weeks ago - Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones - Business Wire
- 6 weeks ago - Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification - Business Wire
- 2 months ago - Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts - Business Wire
- 3 months ago - Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update - Business Wire